Navigation Links
Gene plays dual role in breast cancers with poor prognosis
Date:1/5/2009

A new study reveals that the metadherin gene (MTDH) plays a role in both cancer metastasis and resistance to chemotherapy. The research, published by Cell Press in the January 6th issue of the journal Cancer Cell, identifies MTDH as a promising therapeutic target for high risk breast cancers.

"Most breast cancer patients resist currently available therapeutic regimens and succumb to recurrent tumors that spread to distant vital organs, such as lung, bone, liver and brain," explains senior study author, Dr. Yibin Kang from the Department of Molecular Biology at Princeton University. "Resistance to chemotherapy and metastasis remain major challenges to curative therapy."

Previous research identified several clinically applicable genetic signatures associated with poor clinical outcomes of breast cancer. However, the signatures differed between independent studies, making it difficult to identify overlapping, functionally relevant genes that might be useful for understanding, and eventually preventing, breast cancer metastasis and chemoresistance.

To further unravel the complex genetic events involved in breast cancer, Dr. Kang and colleagues developed a sophisticated computational algorithm designed to identify genomic changes in an extensive collection of breast tumor samples. The researchers discovered abnormally high copy numbers of chromosomal region 8q22 in more than 30% of breast cancers examined. Patients having this type of breast cancer often had a shorter survival time due to recurrent and metastatic cancers.

The researchers went on to find that among a handful of genes in the 8q22 region, MTDH was responsible for both increased metastasis and increased resistance to chemotherapeutics. MTDH protein increased metastasis of breast cancers to distant organs by enhancing the binding of cancer cells to blood vessels in these organs. In addition, MTDH protein promoted cell survival, allowing cancer cells to become more resistant to a wide variety of chemotherapeutic agents that are currently used to treat breast cancer. Further, when the researchers genetically altered the cancer cells to reduce expression of MTDH, the tumor cells became less capable of metastasis and more likely to be eliminated by chemotherapeutic agents.

"These findings establish MTDH as an important therapeutic target for simultaneously enhancing chemotherapy efficacy and reducing metastasis risk," concludes Dr. Kang. "Molecular targeting of MTDH may not only prevent the seeding of breast cancer cells to the lung and other vital organs but also sensitize tumor cells to chemotherapy, thereby stopping the deadly spread of breast cancer."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Laboratory at UI plays major role in diagnosing cancer
2. Environment plays key role in childrens readiness for school
3. Gene Plays Role in Risk of Autism
4. Heart-Shaped Light Displays on Blue Cross Blue Shield of Michigan Building Show Support for American Heart Month, National Wear Red Day
5. Study Spots Gene That Plays Role in Infertility
6. One Million PLAYSTATION(R)3 Users Participate in Folding@home Research Project
7. Gene plays Jekyll and Hyde in brain cancer
8. Gene Plays Jekyll-and-Hyde Role in Deadly Brain Cancer
9. Scientists solve structure of gene regulator that plays key role in cancer
10. Rare Gene Mutation Plays Role in Longevity
11. Price Plays Part in Perceived Power of Medication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... DMG Productions is proud ... Begley, Jr., scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This ... 2008 to address the limitations of fatigue monitoring technologies within the mining industry. ...
(Date:1/23/2017)... Washington, Dc (PRWEB) , ... January 23, 2017 ... ... at American University is taught by healthcare management and evaluation leaders with decades ... from fee-for-service to pay-for-value in the United States healthcare system, there is a ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... (IHCA/INCAL), will serve as a healthcare industry expert at the 2017 Sector Summit ... moderated by Inside Indiana Business host Gerry Dick, will feature an employer and ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... has earned organic certification under the USDA National Organic Program (NOP) for its ... process, we have established organic production and handling systems to complement our current ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and ... Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high quality ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)...  Using Astute Medical,s NephroCheck Test ... kidney injury (AKI) after open-heart surgery and providing ... significantly improved outcomes by reducing the occurrence ... percent, according to a study published ... Medicine. Experience the interactive Multimedia ...
(Date:1/23/2017)... York , January 23, 2017 A ... Prenatal Testing Market was valued at US$0.53 bn in 2013 ... at a strong 17.50% CAGR between 2014 and 2022. The title ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 - ... Non-invasive prenatal ...
(Date:1/23/2017)... , 23. Januar 2017  ResMed (NYSE: ... und 3B Medical ( Winter Haven, Florida ... Vereinbarung über die Beilegung aller globalen Rechtsstreitigkeiten zwischen den ... Verkauf ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren ... an 3B leisten, um das in Florida ...
Breaking Medicine Technology: